Article info
PDFResponse
Clinical use of placebo treatments may undermine the trust of patients: a response to Gold and Lichtenberg
- Correspondence to Dr Pekka Louhiala, Hjelt Institute, University of Helsinki, P.O. Box 41, Helsinki 00014, Finland; pekka.louhiala{at}helsinki.fi
Citation
Clinical use of placebo treatments may undermine the trust of patients: a response to Gold and Lichtenberg
Publication history
- Received April 28, 2014
- Accepted May 22, 2014
- First published June 9, 2014.
Online issue publication
October 20, 2014
Article Versions
- Previous version (9 June 2014).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- What do we really know about the deliberate use of placebos in clinical practice?
- Deliberate use of placebos in clinical practice: what we really know
- The ethics of the placebo in clinical practice revisited
- Patients’ attitudes about the use of placebo treatments: telephone survey
- Physician perspectives on placebo ethics
- Patient attitudes about the clinical use of placebo: qualitative perspectives from a telephone survey
- Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection
- Placebo effects and the molecular biological components involved
- Neurofeedback as placebo: a case of unintentional deception?
- The moral case for the clinical placebo